Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

European Medicines Agency, Scientific Discussion of MabCampath (alemtuzumab)
The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis.
Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions.
SigmaPharm Laboratories Products
Interferon-beta(1b) treatment in neuromyelitis optica.
A randomized controlled phase II trial of riluzole in early multiple sclerosis.
Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.
Biogen Idec receives notification of PDUFA date extension for PLEGRIDY™ (peginterferon beta-1a)
U.S. Patent Office Declares an Interference Between Forward Pharma and Biogen Regarding the Treatment of Multiple Sclerosis With 480 mg Daily Dose of DMF, the Active Ingredient in Tecfidera(R)
Treatment satisfaction in multiple sclerosis.
In vivo time-lapse imaging shows dynamic oligodendrocyte progenitor behavior during zebrafish development.
Boxed warning of HBV risk added to Rituxan, Arezerra
Multifocal Tumefactive Demyelination Mimicking Intracranial Neoplasm.
Biologics-induced autoimmune diseases.
The challenge of comorbidity in clinical trials for multiple sclerosis.
How many injections did you miss last month? A simple question to predict interferon β-1a adherence in multiple sclerosis.
Identical lesion morphology in primary progressive and relapsing-remitting MS -an ultrahigh field MRI study.
Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.
Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity.
Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.
Effects of a 4-month Ananda Yoga Program on Physical and Mental Health Outcomes for Persons With Multiple Sclerosis.
Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results.
Current and future immunotherapy targets in autoimmune neurology.
Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?
A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis.

Pages